Table S8 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

Table S8 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

<p>Differentially expressed genes between pre-αPD-1 Tregs versus post-αPD-1 Tregs, related to Figure 4</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Stéphane Fattori (15048281) (author)
Altres autors:	Aude Le Roy (16991145) (author), Jemila Houacine (16991148) (author), Lucie Robert (16991151) (author), Riad Abes (16991154) (author), Laurent Gorvel (15048296) (author), Samuel Granjeaud (15048278) (author), Marie-Sarah Rouvière (16991157) (author), Amira Ben Amara (16991160) (author), Nicolas Boucherit (16991163) (author), Carole Tarpin (16991166) (author), Jihane Pakradouni (16991169) (author), Emmanuelle Charafe-Jauffret (15090456) (author), Gilles Houvenaeghel (16991172) (author), Eric Lambaudie (16991175) (author), François Bertucci (10820542) (author), Philippe Rochigneux (15048269) (author), Anthony Gonçalves (15048284) (author), Arnaud Foussat (16991178) (author), Anne-Sophie Chrétien (16991181) (author), Daniel Olive (15048311) (author)
Publicat:	2025
Matèries:	Cancer Tumor Biology Therapeutic Research and Development Immuno-oncology Methods and Technology Breast Cancer Immunology Regulatory T cells Immunotherapy Combination immunotherapy Single Cell Technologies Translational Research Tumor Microenvironment
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S7 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
per: Stéphane Fattori (15048281)
Publicat: (2025)

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
per: Hiroshi Kagamu (14961732)
Publicat: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
per: Hansol Lee (15054787)
Publicat: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
per: Hansol Lee (15054787)
Publicat: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
per: Hansol Lee (15054787)
Publicat: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
per: Hansol Lee (15054787)
Publicat: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
per: Arianna Draghi (15126339)
Publicat: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
per: Arianna Draghi (15126339)
Publicat: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
per: Arianna Draghi (15126339)
Publicat: (2025)

Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
per: Francisco Exposito (16721403)
Publicat: (2025)

Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
per: Francisco Exposito (16721403)
Publicat: (2025)

Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
per: Francisco Exposito (16721403)
Publicat: (2025)

Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
per: Francisco Exposito (16721403)
Publicat: (2025)

Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
per: Francisco Exposito (16721403)
Publicat: (2025)

Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx
per: Yueren Fan (22687577)
Publicat: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
per: Andrew O. Yam (15293045)
Publicat: (2025)

Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
per: Sung-Eun Lee (14855067)
Publicat: (2025)

Supplementary Table S2 from Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
per: Dong-Chun Hong (16374308)
Publicat: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
per: Lavanya Sivapalan (15314248)
Publicat: (2025)

Figure 1 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
per: Massimiliano Mellone (14959419)
Publicat: (2025)

Figure 2 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
per: Massimiliano Mellone (14959419)
Publicat: (2025)

Figure 3 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
per: Massimiliano Mellone (14959419)
Publicat: (2025)

Figure 4 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
per: Massimiliano Mellone (14959419)
Publicat: (2025)

Figure 5 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
per: Massimiliano Mellone (14959419)
Publicat: (2025)

Figure 6 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
per: Massimiliano Mellone (14959419)
Publicat: (2025)

Macros for image quantification from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
per: Massimiliano Mellone (14959419)
Publicat: (2025)

Supplementary Data 2 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
per: Massimiliano Mellone (14959419)
Publicat: (2025)

Supplementary Data 3 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
per: Massimiliano Mellone (14959419)
Publicat: (2025)

Supplementary Data 4 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
per: Massimiliano Mellone (14959419)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_fslqq9ubml1gi1nirfu0ldce0c